title: Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
authors.forename: G T
authors.initials: GT
authors.lastname: Spear
authors.forename: G
authors.initials: G
authors.lastname: Olinger
authors.forename: B L
authors.initials: BL
authors.lastname: Sullivan
authors.forename: A L
authors.initials: AL
authors.lastname: Landay
authors.forename: H
authors.initials: H
authors.lastname: Kessler
authors.forename: E
authors.initials: E
authors.lastname: Connick
authors.forename: D
authors.initials: D
authors.lastname: Kuritzkes
authors.forename: M
authors.initials: M
authors.lastname: St Clair
authors.forename: J
authors.initials: J
authors.lastname: Spritzler
authors.forename: H
authors.initials: H
authors.lastname: Wu
authors.forename: M M
authors.initials: MM
authors.lastname: Lederman
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003171:Complement Pathway, Classical; D003165:Complement System Proteins / Q000032:analysis*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015483:HIV Antibodies / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015483:HIV Antibodies; D015488:HIV Antigens; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D003165:Complement System Proteins; D019438:Ritonavir